Compare Enveric Biosciences Inc (ENVB) vs Genuine Parts Company (GPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Genuine Parts Company — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Genuine Parts Company trades at $127.56 (market cap $17.29B). The key difference: Genuine Parts Company is far larger — about 2584.5× Enveric Biosciences Inc's market cap, and Genuine Parts Company pays a 3.39% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Genuine Parts Company for 75 Days on average.
| ENVB | GPC | |
|---|---|---|
Market Cap | $6.69M | $17.29B |
Volume | 41,141 | 900,870 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $149.26 |
52-Week Low | $1.27 | $92.47 |
Typical Hold Time | 14 Days | 75 Days |
Enterprise Value | -$1.60M | $23.38B |
Dividend Yield | — | 3.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
GPC trades at $128.17, up 0.62% today, with a bearish technical signal but neutral oscillators. The company reported mixed earnings, missing in Q4 2025 but beating in Q1 and Q2 2026, with Q3 2026 results due October 20, 2026. Revenue grew to $24.3B in 2025, but net income margin fell sharply to 0.13%. Analyst consensus is a Buy with a $145.75 price target, and the upcoming spinoff of the industrial unit Motion in Q1 2027 is a key catalyst.
The outlook is cautiously optimistic due to the spinoff potential and dividend stability, but risks include declining profitability, high P/E ratio of 501.64, and bearish technical trends. Investors should weigh the long-term benefits of the separation against near-term margin pressures and debt levels rising to 23.08% of assets in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →
